Results 161 to 170 of about 48,247 (244)

Dual Ligand‐Enabled Nondirected C─H Olefination of (Hetero)Arenes for the Synthesis of Clickable Derivatives

Chemistry – A European Journal, EarlyView.
We report an efficient method for late‐stage installation of “clickable” alkyne groups into diverse (hetero)arenes. Using a dual‐ligand palladium catalyst that combines an NASA ligand with an N‐heterocycle, an acrylate unit bearing a terminal alkyne can be introduced via nondirected C─H activation.
Tommaso Braga, Maria Hergert, Manuel van Gemmeren   +2 more
wiley   +1 more source

Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs. [PDF]

World J Hepatol
Dobrowolska K, Zarębska-Michaluk D, Pawłowska M, Tudrujek-Zdunek M, Lorenc B, Berak H, Janczewska E, Mazur W, Janocha-Litwin J, Klapaczyński J, Sitko M, Dybowska D, Parfieniuk-Kowerda A, Piekarska A, Jaroszewicz J, Flisiak R.   +15 more
europepmc   +1 more source

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, EarlyView.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy. [PDF]

Clin Mol Hepatol
Witte M, Oltmanns C, Tauwaldt J, Schmaus H, Mischke J, Grabert G, Bretthauer M, Roesner LM, Werfel T, Deterding K, Maasoumy B, Wedemeyer H, Kacprowski T, Kraft ARM, Cornberg M.   +14 more
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Risk factors for virological relapse and long-term efficacy of direct-acting antiviral agents in chronic hepatitis C infection: Impact of HIV coinfection and renal function changes. [PDF]

Medicine (Baltimore)
Deng M, Li Q, Zhang Z, Chen Z.
europepmc   +1 more source

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, EarlyView.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Letter to the editor on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study". [PDF]

Clin Mol Hepatol
Wang Q, Qian Z, Yang X, Chen D, Wang X, Chen F.   +5 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source